Terms: = Lung cancer AND MYO5A, Q9Y4I1, MYR12, MYO5, MYH12, GS1, ENSG00000197535, 4644 AND Treatment
3 results:
1. Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell lung cancer: Pooled Analysis of 7 Clinical Trials.
Li LX; Cappuzzo F; Matos I; Socinski MA; Hopkins AM; Sorich MJ
Oncologist; 2023 Apr; 28(4):e205-e211. PubMed ID: 36905578
[TBL] [Abstract] [Full Text] [Related]
2. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
Barrington DA; Riedinger C; Haight PJ; Tubbs C; Cohn DE
Gynecol Oncol; 2022 Jun; 165(3):500-505. PubMed ID: 35422338
[TBL] [Abstract] [Full Text] [Related]
3. RYR2 mutation in non-small cell lung cancer prolongs survival via down-regulation of DKK1 and up-regulation of gs1-115G20.1: A weighted gene Co-expression network analysis and risk prognostic models.
Ren W; Li Y; Chen X; Hu S; Cheng W; Cao Y; Gao J; Chen X; Xiong D; Li H; Wang P
IET Syst Biol; 2022 Apr; 16(2):43-58. PubMed ID: 34877784
[TBL] [Abstract] [Full Text] [Related]
